James Freeman, MD
Ophthalmology · Memphis, TNNPI 1902805823
Payments from drug & device makers
What this record shows
This record is dominated by ownership interests: $127,500 of the $140,887 with a category attached, or 90.5%. Grace Medical, Inc. accounts for 90.5% of it on its own, with 36 other manufacturers making up the rest. Reporting peaked in 2022 at $128,554 and has fallen 99.1% since, to $1,178 in 2025. Among ophthalmology clinicians in TN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 279 payments — averaging $504.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Grace Medical, Inc.$128K
- Rxsight Inc$7K
- AbbVie$961
- Johnson & Johnson Surgical Vision, Inc.$585
- Bausch & Lomb Americas Inc.$499
- Bausch & Lomb, A Division Of Bausch Health US, LLC$443
- plus $4K from 31 others
Across 3 payments — averaging $2100.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Johnson & Johnson Surgical Vision, Inc.$6K
What the payments were for
- Consulting fees$1,5001%
- Speaking & faculty fees$260%
- Food & beverage$6,3805%
- Education$5,4374%
- Gifts$450%
- Ownership interest$127,50090%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- RXSIGHT CONTACT LENS$7,023
- RXSIGHT INJECTOR CARTRIDGE$7,023
- RXSIGHT INJECTOR HANDPIECE$7,023
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$7,023
- RXSIGHT LIGHT ADJUSTABLE LENS (RXLAL)$5,344
- LIGHT ADJUSTABLE LENS (LAL)$1,679
- VisuMax$186
- iDoseTR$128
- OMIDRIA$125
- TEPEZZA$111
- INVELTYS$104
- EYSUVIS$104
- BROMSITE$102
- ENVISTA ENVY IOL$101
How this compares
$140,887 in reported general payments places this provider in the 95th percentile of 323 ophthalmology providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 66 | $78,228 |
| RocklatanNetarsudil Mesylat/Latanoprost | 77 | $48,189 |
| XiidraLifitegrast | 19 | $35,148 |
| Loteprednol Etabonate | 171 | $34,721 |
| LumiganBimatoprost | 50 | $30,591 |
| CombiganBrimonidine Tartrate/Timolol | 55 | $18,391 |
| Prednisolone Acetate | 283 | $14,108 |
| VyzultaLatanoprostene Bunod | 35 | $11,540 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 50 | $9,533 |
| ProlensaBromfenac Sodium | 26 | $8,826 |
| Cyclosporine | 13 | $8,678 |
| RhopressaNetarsudil Mesylate | 13 | $6,233 |
| Alphagan PBrimonidine Tartrate | 20 | $6,189 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 19 | $5,618 |
| Latanoprost | 481 | $5,322 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan, Alphagan P | $961 | $133,398191 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $44 | $54,42190 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate, Prolensa, Lotemax Sm, Lotemax | $443 | $52,209227 claims |
| Bausch & Lomb Americas Inc.Xiidra, Vyzulta | $499 | $46,68854 claims |
| AlconSimbrinza | $330 | $5,61819 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 323 ophthalmology providers in Tennessee.
Other ophthalmology in Memphis
- Melissa ToyosMemphis$1.3M
- Rolando ToyosMemphis$809K
- Brian FowlerMemphis$206K
- Brian JerkinsMemphis$150K
- John FreemanMemphis$136K
- Penny AsbellMemphis$131K
- Kourtney HouserMemphis$104K
- Subba GollamudiMemphis$67K
- Andrew CrothersMemphis$13K
- Brian SmithMemphis$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.